Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903554 | 0.86 | GRM5 (0.39) | GRM5 | |
| SCHEMBL9903388 | 0.83 | ALDH1A1 (0.39) | GRM5PDGFRBKDRALDH1A1 | |
| SCHEMBL9903330 | 0.82 | CHRNB2 (0.41) | GRM5PDGFRB | |
| SCHEMBL9903123 | 0.81 | GRM5 (0.49) | PIK3CGGRM5PDGFRBALDH1A1 | |
| SCHEMBL9903429 | 0.78 | GRM5 (0.47) | PIK3CGGRM5PDGFRB | |
| SCHEMBL9903707 | 0.77 | GRM5 (0.55) | GRM5PDGFRBFFAR1 | |
| SCHEMBL9903402 | 0.76 | FFAR1 (0.39) | PIK3CGGRM5PDGFRBFFAR1 | |
| SCHEMBL9903655 | 0.75 | EGLN1 (0.40) | GRM5 | |
| SCHEMBL9902798 | 0.74 | BRAF (0.38) | GRM5PDGFRBALDH1A1 | |
| SCHEMBL9903508 | 0.73 | CHRNB2 (0.35) | PIK3CGGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | PIK3CG 2169/4885GRM5 1/4885CYP11B1 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.